Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers.
Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells (NK Cell), etc., work collectively to protect the body against cancer by aiming at abnormal antigens articulated on the facade of the tumor cells.Therapies including granulocyte colony-stimulating factor (G-CSF), imiquimod, interferons as well as parts of cellular membrane from bacteria are approved for medical use. Some of the others such as IL-7, IL-2, IL-12, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans anda variety of chemokines are involved in preclinical and clinical studies.
Ask For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/525
An increase in the prevalence of cancer and a number of autoimmune diseases, the demand for immunotherapy drugs is likely to increase. Moreover, with the rising need for mAbs, the immunotherapy drugs market is anticipated to have a positive outlook till the end of the forecast period 2016-2024. MAbs have a high affinity towards the specific disease cells as well as areas that require treatment. Accordingly, they can be utilized for therapies such asantibody-directed enzyme prodrug therapy and radio immunotherapy. The increaseduse of these antibodies in the drug development processis likely toaid to boost the market’s revenue making capacity over the forecast period.
Another important factor driving the growth prospects ofthe global immunotherapy drugs market is the materialization of biosimilars. Dissimilarto generic drugs that have active pharmaceutical ingredients alikeoriginal drugs, biosimilars are nearly identical to their creator biologic compounds. In view of the fact that biosimilars are less expensive and aid to make managementof diseases more reachable for the patients than biologics, the sale of biosimilars among the patients and hospitals alike is likely to riseconsiderably during the forecast period thereby augmenting the overall growth of the immunotherapy drugs market.
According to National Cancer Institute, around 1,685,210 new cases of cancer are likely to be diagnosed in the U.S. in 2016 and about 595,690 people are estimated to die from the disease. Since immunotherapy is used as a first line of treatment in the management of cancer, the market immunotherapy drugs market will grow accordingly. North America is the largest region in the global immunotherapy drugs market and is expected to retain its dominance over the forecast period. Asia Pacific is likely to be the fastest-growing marketover the forecast period. The elevated growth of this region can mainly be attributed to low cost of manufacturing of these drugs in the region, rising occurrence of cancer and favorable regulatory framework in this region.
Some of the companies operating in the immunotherapy drugs market in the current scenario are GlaxoSmithKline, F. Hoffmann-La Roche AG, AbbVie, In., Merck & Co., Inc. Amgen, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZeneca plc and Johnson & Johnson. Click To Read More On Immunotherapy Drugs Market